COVID Moonshot uses synthesis-directed de novo design for SARS-CoV-2 main protease inhibitors
A machine-learning de novo design model was coupled with synthesis route prediction in the COVID Moonshot campaign against the SARS-CoV-2 main protease. The authors report novel chemical scaffolds that are active in biochemical and live-virus assays and were synthesized along model-generated routes. The abstract gives no potency figures, so the strength of the result should be checked in the full text.
Technology: Synthesis-directed de novo design model with synthesis route prediction
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Novel scaffolds designed with machine learning and synthesized along model-generated routes were tested in biochemical and live-virus assays.
- Still unknown: Not reported.
- AI role: Machine-learning de novo design model coupled with synthesis route prediction in the COVID Moonshot campaign.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1039/d1cc00050k&resultType=core&format=json
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 90 of works of the same type, year and subfield (OpenAlex work metrics, 36 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.